SAB Biotherapeutics announces Fast Track and Breakthrough Therapy designations for SAB-176 anti-influenza candidate

SAB Biotherapeutics, Inc.

Fast Track Designation granted by FDA for SAB-176, an anti-influenza polyclonal antibody therapy.
Breakthrough Therapy Designation also received for SAB-176, potentially expediting development and review.
Company published an updated corporate strategy presentation on its website discussing these designations and platform.
SAB-176 targets influenza; regulatory milestones may accelerate clinical timeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.